NEW YORK CITY, NEW YORK/ ACCESS Newswire/ June 5, 2025/ New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12- part media partnership with ...

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Austin, Texas, United States, June 6th, 2025, FinanceWireThe Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network ...